Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Net Income

Bottom-line profit after all expenses, interest, and taxes.

Accendra Health, Inc.NYSE: ACH

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$6.47M, compared with -$24.98M a year earlier. Trailing-twelve-month net income was -$1.08B.

Context

  • Net income amounted to 39.8% of revenue in FY2025, up 36.5 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $1.24M (+100.1%) for the fiscal year ending Dec 2026, a step up from the -203.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.47M+88.5% QoQ
Last fiscal yearDec 2025
-$1.1B-203.5% YoY
LTMMar 2026
-$1.08B-195.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+74.1%+99.3%+25.2 pp
1 year-203.5%+100.1%+303.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(1.1B) USD
Year-over-year change
-203.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -195.8% is the 10th highest of 11, against a peer median of +27.9%.
  • Net income amounts to 39.8% of revenue for ACH, versus a peer median of 103.3%.
ACH Competitors
Net Income for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGHTSight Sciences, Inc.LTM Mar 2026-$37.25M USD+24.6%—46.8%
HITIHigh Tide Inc.LTM Apr 2026-CA$44.03M CAD-355.0%—6.6%
CVRXCVRx, Inc.LTM Mar 2026-$52.66M USD-2.2%—89.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
OMOutset Medical, Inc.LTM Mar 2026-$74.85M USD+34.2%—63.7%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.1%——
CABACabaletta Bio, Inc.LTM Mar 2026-$175.43M USD-38.4%——
CGCCanopy Growth CorporationLTM Mar 2026-CA$366.64M CAD+38.7%—117.4%
ACHAccendra Health, Inc.LTM Mar 2026-$1.08B USD-195.8%—39.8%
Peer median (excluding ACH) —+27.9%—103.3%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.